Phase III
No mentions found
This entity hasn't been tracked yet, or Iris is still building its knowledge base.
Related Articles from SNS
When drug discovery fails: scientists share their frustrations with the process
Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer).
India to build 52‑satellite surveillance grid to monitor China, Pakistan threats
Space is often called the final frontier, and India is taking decisive steps to establish a strong presence there. Its primarily civilian space programme is now expanding to build a robust military space architecture. The government has sanctioned a 52‑satellite constellation under the Space Based Surveillance Phase III initiative, to be rolled out from 2025 to 2029.
A Pan-Cancer Multi-Omic SuperLearner for Regulated Cell Death Survival Topologies
Introduction: Regulated cell death (RCD) pathways profoundly influence tumor progression and immune modulation. In prior work, we constructed a comprehensive database mapping 25 forms of RCD across seven multi-omic layers encompassing 33 tumor types (CancerRCDShiny). Despite their robust ability to identify risk populations, translating these prognostic signatures into personalized clinical workflows requires a shift from generalized cohort stratification to individualized risk mapping.
A first-in-class pulsatile FXR agonist for bile-acid-related liver diseases
Abstract Nuclear receptors are central regulators of metabolism1, yet therapeutic strategies that enforce continuous receptor activation frequently lead to reduced efficacy and unacceptable toxicity. Here we report a first-principles drug design strategy that aligns pharmacokinetics with physiological signalling cycles. We developed linafexor, a potent non-bile-acid agonist of the farnesoid X receptor (FXR)2; it is engineered for rapid systemic clearance, which enables pulsatile receptor...
Hearing loss is bad for the whole body – but new treatments are coming
I’m sitting in a soundproof booth at an audiologist’s office, wearing headphones and straining to hear some faint electronic noises. When I think I’ve heard one, I press a button. Was that real or did I imagine it?
UK's GSK to acquire U.S. drugmaker Nuvalent for $10.6 billion as pharma giants race to expand pipelines
U.K. pharmaceutical group GSK has entered an agreement to acquire U.S.-based drugmaker Nuvalent for $10.6 billion to bolster its lung cancer pipeline, in what would be the British drugmaker's largest acquisition in more than a decade. The all-cash deal values Nuvalent at about $124 per share, according to a GSK filing on Tuesday, representing a 40% premium to its last closing price. The Financial Times had reported the transaction earlier on Tuesday.
Doctors thought this kidney drug helped some patients. It may help millions more.
Doctors thought this kidney drug helped some patients. It may help millions more. - Date: - June 8, 2026
Chase: Expectations raised in Cincy with better D
CINCINNATI -- Ja'Marr Chase wasn't shy about letting everyone know the Cincinnati Bengals needed to improve defensively. It was so blatantly obvious to Chase last year that he didn't feel the need to explicitly point it out as the Bengals sputtered to a third straight year without a playoff appearance. This year at the Pro Bowl Games, Chase said he was not subtle about recruiting players to join the Bengals.
Cancer patients found a simple way to stay mentally sharp during chemotherapy
Cancer patients found a simple way to stay mentally sharp during chemotherapy A simple exercise routine may help protect cancer patients from “chemo brain,” with researchers finding noticeable improvements in attention and cognitive function during treatment. - Date: - June 9, 2026 - Source: - Wiley - Summary: - “Chemo brain” affects up to 80% of people receiving chemotherapy, making everyday tasks harder.
Is the peptide craze backed by science? The promise behind the hype
Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer).